TMS Referral and Access in San Antonio: The Short Answer
Pursuing a TMS referral in San Antonio generally means two connected steps: a conversation with a clinician about whether repetitive transcranial magnetic stimulation (rTMS) may be appropriate for your situation, and then a structured pre-treatment evaluation before any treatment decision is made. The referral is not the treatment, and the evaluation is not a formality. Together they are how a care team decides whether a noninvasive brain-stimulation option fits, and how safety questions get answered before anything begins.[source][source]
The National Institute of Mental Health (NIMH) describes rTMS as a noninvasive therapy that uses repeated magnetic pulses to stimulate targeted brain circuits, delivered in an office setting without anesthesia. The American Psychiatric Association and National Network of Depression Centers consensus recommendations describe the evaluation as a structured process that reviews seizure and neurologic history, medicines and substances that may affect seizure threshold, sleep, other medical factors, and metal or implanted devices near the head and neck. Those are the two halves of the pathway: what the treatment is, and what a clinician needs to know before considering it.[source][source]
This article explains that general process and safety screening only. It cannot tell you whether you personally qualify, and it is not a diagnosis, a treatment plan, or a substitute for a clinical conversation. TMS Health's public site lists TMS Evaluation, TMS Therapy, an Accelerated Program, Remission and Maintenance TMS, and Telemedicine as service categories; this guide does not confirm scheduling, insurance coverage, or eligibility details, which should be verified directly with the clinic.
Who Typically Explores TMS, and Why Prior Treatment History Matters
NIMH states that the first rTMS device was FDA-cleared in 2008 for depression after an inadequate response to at least one antidepressant in the current episode. That single sentence explains most of the referral conversation. Clinicians ask about earlier treatments not to judge anyone, but because the regulatory and clinical context for rTMS is built around treatment-resistant depression, where at least one medication trial in the current episode has not worked well enough.[source]
It is worth being precise about the word "cleared." FDA clearance is a regulatory pathway for Class II devices, distinct from the agency's approval pathway for drugs. The FDA's special-controls guidance for rTMS systems describes the device as an external electromagnetic device that delivers repetitive pulsed magnetic fields to activate neurons within a limited cortical volume, and it frames safety through labeling, trained use, and patient- and device-specific contraindications and warnings. Current device labeling, not a general article, governs which indications apply to a specific device.[source]
None of this determines whether a particular person qualifies. It describes the general context in which a referral conversation happens, and it explains why a clinician will want a clear history of what has been tried, for how long, and with what result.
What a Pre-Treatment TMS Evaluation Screens For
A TMS evaluation is a safety review as much as a suitability review. The consensus recommendations describe screening domains rather than a single pass-or-fail test. The table below summarizes what a trained clinician typically weighs; it is a preparation aid, not a checklist you can use to clear or exclude yourself.[source]
| Domain | What the clinician is trying to learn | Why it matters |
|---|---|---|
| Seizure history | Any personal history of seizures or seizure-like events | Seizure is a known but uncommon risk of rTMS; history shapes risk assessment |
| Neurologic history | Prior neurologic conditions, head injury, or other relevant diagnoses | Provides context for individualized risk and protocol decisions |
| Medicines and substances | Prescriptions, supplements, and substances that may lower seizure threshold | Some agents interact with stimulation risk and may need discussion |
| Sleep | Recent sleep deprivation or major sleep disruption | Sleep deprivation is a recognized factor clinicians consider |
| Other medical factors | Relevant medical conditions and current health status | Supports a whole-person safety review |
| Metal and implanted devices | Ferromagnetic or magnet-sensitive material near the head and neck, and certain implanted devices | Magnetic fields can interact with some materials and devices |
How a Referral Conversation Usually Proceeds
The order of events is generally straightforward, though the details vary by clinic. First comes a discussion of symptoms and prior treatment history, including what has been tried and how it went. Next comes gathering medical and medication information, which is where the screening domains above come into play. Then a structured evaluation follows, which may include determining an individual motor threshold and the treatment location, because stimulation settings are individualized rather than fixed.[source][source]
The general sequence, at a high level
- Raise the question Discuss symptoms and prior treatments with a clinician and ask whether rTMS is worth evaluating.
- Gather information Collect medication, supplement, medical, neurologic, and sleep history, plus any metal or implanted devices near the head and neck.
- Complete a structured evaluation A trained clinician reviews the information and may determine individual motor threshold and treatment location.
- Discuss the plan If treatment is considered appropriate, the clinician explains the proposed schedule, what to expect, and follow-up.
Standard Versus Accelerated Schedules: What the Evidence Does and Does Not Show
NIMH describes a typical rTMS course as about five sessions per week for four to six weeks, with individual sessions lasting roughly 3 to 40 minutes. Accelerated protocols differ from that pattern, often compressing treatment into fewer days with multiple sessions per day. The practical question patients ask is whether faster is better, and the honest answer is that the evidence is mixed rather than settled.[source]
A 2025 systematic review compared accelerated protocols with standard or sham rTMS in depression. Some included studies suggested potential advantages for selected accelerated schedules, such as certain twice-daily high-frequency protocols and intensive iTBS protocols, while other studies found no significant difference. The review emphasizes that dose, the interval between sessions, targeting method, small samples, limited independent replication, and inconsistent patient definitions prevent a definitive conclusion. In plain terms: accelerated schedules are an active area of research, not a proven universal upgrade.[source]
That is why the choice between standard and accelerated schedules is a clinical conversation, not a consumer preference. A clinician weighs the evidence, the individual situation, and practical factors, and no schedule guarantees a particular outcome.
Common Short-Term Effects Patients Ask About
Side effects are often the question that stalls a referral, so it helps to know what is commonly described. NIMH lists scalp discomfort, facial or jaw muscle sensations, mild headache, brief lightheadedness, and dizziness as common short-term effects. Seizure is possible but uncommon when expert safety guidance is followed. The FDA guidance similarly identifies seizure, scalp discomfort or burn, effects on other medical devices, hearing effects, and electromagnetic interference among the risks addressed by device controls.[source][source]
These are general descriptions, not predictions for any individual. A clinician discusses what to expect, what to report, and how concerns are handled in a specific care setting.
Questions to Bring to a San Antonio TMS Consultation
A referral conversation goes better when you arrive with specific questions. The list below is organized around the domains the consensus recommendations describe, so each question maps to something a clinician actually needs to discuss.[source]
| Topic | Question to ask |
|---|---|
| Prior treatment | Which earlier treatments and timeframes are relevant to this discussion? |
| Seizure and neurologic history | Does anything in my history need to be reviewed before stimulation is considered? |
| Medicines and supplements | Should I list everything I take, including over-the-counter products and supplements? |
| Metal and implanted devices | What should I disclose about metal, implants, or devices near my head and neck? |
| The evaluation itself | What does the evaluation involve, and what will be measured or determined? |
| Protocol settings | How are stimulation settings individualized, and who determines them? |
| Follow-up | What does follow-up look like during and after a course of treatment? |
| Telemedicine | Which parts of the process, if any, can be handled remotely? |
What This Guide Cannot Tell You
This is general patient education. It is not a diagnosis, a treatment recommendation, medication guidance, or emergency triage. If you are in crisis or need urgent help, contact local emergency services rather than relying on an article. Screening quizzes can support a conversation with a clinician, but they do not diagnose a condition and are not clinical determinations; individual candidacy requires a structured evaluation by a trained clinician.[source]
Specific addresses, phone numbers, appointment availability, insurance coverage, and current program details should be confirmed from the clinic's current public site or in a direct conversation. Product-specific capability and outcome claims are outside the scope of this article.
Next steps
For current appointment, location, or contact information, visit the official website.[source]
Frequently Asked Questions
Do I need a referral to get a TMS evaluation in San Antonio?
Referral requirements and intake steps vary by clinic and are operational details that this guide does not confirm. The most reliable approach is to ask the clinic directly about its current process, and to ask your own clinician whether they would support a referral.
Is TMS FDA-approved?
The more accurate term is FDA-cleared. NIMH notes that the first rTMS device was FDA-cleared in 2008 for depression after an inadequate response to at least one antidepressant in the current episode, and FDA clearance is a different regulatory pathway from drug approval. Current device labeling governs which indications apply to a specific device, so clearance should not be extended to unspecified devices, accelerated protocols, or populations.
How long does a typical TMS course take?
NIMH describes a typical course as about five sessions per week for four to six weeks, with individual sessions lasting roughly 3 to 40 minutes. Accelerated protocols differ from that pattern. An individual plan is set by the treating clinician, and no timeline guarantees a particular result.
Does accelerated TMS work better than standard TMS?
The evidence is mixed. A 2025 systematic review found that some studies suggested potential advantages for selected accelerated schedules, while others found no significant difference. Small samples, inconsistent definitions, differences in dose and targeting, and limited independent replication prevent a definitive conclusion, so accelerated schedules should not be described as universally superior or as producing faster remission.
What will a TMS evaluation ask me about?
Consensus recommendations describe screening for seizure history, neurologic history, medicines or substances that may alter seizure threshold, sleep deprivation, other relevant medical factors, and ferromagnetic or magnet-sensitive material near the head and neck or certain implanted devices. A trained clinician interprets these factors, and device labeling governs current contraindications.
Can a screening quiz tell me whether TMS is right for me?
No. A screening quiz can help you organize your thoughts and prepare for a conversation, but it does not diagnose a condition and is not a clinical determination. Individual candidacy requires a structured evaluation by a trained clinician.
What are the common short-term side effects?
NIMH describes scalp discomfort, facial or jaw muscle sensations, mild headache, brief lightheadedness, and dizziness as commonly reported short-term effects. Seizure is possible but uncommon when expert safety guidance is followed. These are general descriptions, not personalized risk estimates.
Can telemedicine replace an in-person TMS evaluation?
TMS Health's public site lists Telemedicine as a service category, but this guide does not confirm which evaluation components can be completed remotely. Ask the clinic directly about the current process rather than assuming a virtual visit can substitute for an in-person assessment.
References
- APA and NNDC consensus recommendations for clinical rTMS in major depressive disorder — pmc.ncbi.nlm.nih.gov
- Comparison between accelerated and standard or sham rTMS in depression: 2025 systematic review — pubmed.ncbi.nlm.nih.gov
- FDA Class II special controls for rTMS systems used for major depressive disorder — www.fda.gov
- NIMH brain stimulation therapies: rTMS patient evidence summary — www.nimh.nih.gov
- Official website — tms-heal.com
Leave a Reply